Skip to main content

Table 2 Univariate and Multivariable Competing Risks Model for Death in ESRD Patients (n = 109)

From: Evaluation of laboratory values affecting mortality of end-stage renal disease patients: a competing risks approach

Variables

 

Univariate

Multivariable

 

S-HR

(80% HPD Region)

Adjusted S-HR

(90% HPD Region)

Age

 

1.02 (1.004–1.04)*

1.02 (0.99–1.04)

Ferritin

 

1 (0.99–1.001)

 

Creatinine

 

0.96 (0.92–1.01)

 

Cholesterol

 

0.99 (0.98–0.997)*

0.99 (0.98–1.001)

Uric acid

 

0.89 (0.76–1.06)

 

SGOT

 

1.02 (0.99–1.05)

 

SGPT

 

0.98 (0.96–1.01)

 

‌Sodium

 

0.98 (0.89–1.07)

 

‌FBS

 

1 (0.99–1.005)

 

‌Triglycerides

 

0.997 (0.99–1.002)

 

Sex

Male

5.84 (1.97–15.26)*

4.64 (1.36–15.49)**

Hemoglobin

   
 

\(\le\)10

1.02 (0.59–1.84)

 
 

10-12.5

> 12.5

1

1.58 (0.89–2.87)

 

Potassium

   
 

3.5–5.5

1

 
 

> 5

1.03 (0.63–1.66)

 

ALP

   
 

\(\le\)300

1

 
 

> 300

0.93 (0.59–1.51)

 

Calcium

   
 

\(\le\)8.6

1.23 (0.68–2.31)

1.26 (0.54–3.02)

 

8.6–9.5

\(\ge\)9.5

1

1.64 (0.91–3.14)

--

2.33 (1.05–5.32)**

Phosphorus

   
 

\(<\)5

1

 
 

\(\ge\)5

1.15 (0.69–1.82)

 

iPTH

   
 

\(\le\)150

1.97 (1.05–3.88)*

2.56 (1.09–6.15)**

 

150–600

1

--

 

> 600

1.26 (0.71–2.23)

1.24 (0.58–2.65)

Albumin

   
 

< 4

1

 
 

\(\ge\)4

0.78 (0.46–1.27)

 
  1. S-HR: Sub-hazard ratio; HPD region: highest posterior density region; SD: Standard deviation; SGOT: serum glutamic-oxaloacetic transaminase; SGPT: serum glutamic-pyruvic transaminase; FBS: fasting blood sugar; ALP: Alkaline Phosphatase; iPTH: intact parathyroid hormone
  2. * Significant at α = 0.2, ** Significant at α = 0.1